Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Silence Therapeutics Plc (SLN.LN)

Silence Therapeutics Plc (SLN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases

New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases Data presented at 2021 ASH annual meeting...

SLN.LN : 535.000 (-0.93%)
SLN : 21.99 (+3.24%)
Silence Therapeutics Welcomes Deep Track Capital as New Shareholder

1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel...

SLN.LN : 535.000 (-0.93%)
SLN : 21.99 (+3.24%)
Silence Therapeutics Begins Exclusive Nasdaq Trading

Silence Therapeutics Begins Exclusive Nasdaq Trading 30 November 2021 LONDON, Silence Therapeutics plc, Nasdaq:SLN ("Silence" or "the Company"), a...

SLN.LN : 535.000 (-0.93%)
SLN : 21.99 (+3.24%)
Silence Therapeutics to Present at Jefferies London Healthcare Conference

Silence Therapeutics to Present at Jefferies London Healthcare Conference 11 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN...

SLN.LN : 535.000 (-0.93%)
Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder

Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder 5 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN...

SLN.LN : 535.000 (-0.93%)
SLN : 21.99 (+3.24%)
Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market

Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq...

SLN.LN : 535.000 (-0.93%)
SLN : 21.99 (+3.24%)
Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform

Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform Hansoh will make a $16...

SLN.LN : 535.000 (-0.93%)
SLN : 21.99 (+3.24%)
Silence Therapeutics to Host R&D Day on October 21, 2021

Silence Therapeutics to Host R&D Day on October 21, 2021 7 October 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the...

SLN.LN : 535.000 (-0.93%)
SLN : 21.99 (+3.24%)
Silence Announces Mallinckrodt Exercise of Options for Two Additional Complement Targets

Silence Announces Mallinckrodt Exercise of Options for Two Additional Complement Targets

SLN.LN : 535.000 (-0.93%)

Barchart Exclusives

Earnings, the Yen and Other Key Things to Watch This Week
This week is relatively quiet on the news front, but there are still earnings due out and plenty of other macro factors to watch. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar